Eagle Pharmaceuticals (EGRX) Misses Q2 EPS by $1.80
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Eagle Pharmaceuticals Reports Second Quarter 2022 Results
August 9, 2022 6:50 AM EDTÂ Â Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share
  Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily reflecting product sales of vasopressin and PEMFEXY®
  First half 2022 adjusted non-GAAP earnings per diluted share1 more than doubled to $5.60 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Companys history
  First half 2022 revenue of $190 million exceeds full year 2021 revenue of $171.5 million
 ... More
